Market OverviewThe global Epilepsy Drugs Market is valued at USD 10.63 billion in 2024 and is projected to reach a value ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and ...

For too long, health care providers have had few options to offer patients much-needed symptom improvement,” Bill Martin, PhD, Global Therapeutic Area Head, Neuroscience, Johnson & Johnson ...

The nasal spray was first approved by the FDA in 2019 as a supplemental treatment, along with an oral medication, for the approximately one-third of people with MDD who struggle with ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.